Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer
摘要:
c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a number of approaches to disrupt aberrant c-Met signaling. Screening efforts identified a unique class of 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1. Subsequent SAR studies led to the development of 81 (MK-2461), a potent inhibitor of c-Met that was efficacious in preclinical animal models of tumor suppression. In addition, biochemical studies and X-ray analysis have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase. This report details the development of 81 and provides a description of its unique biochemical properties.
Synthesis of mono- and bis(aminomethyl)dioxanes fromN-[3-(2-chloroethoxy)-2-hydroxypropyl]sulfamates
摘要:
N-Substituted aminomethyl- and 2,5-bis(aminomethyl)-1,4-dioxanes were prepared by cyclization of the corresponding potassium N-[3-(2-chloroethoxy)-2-hydroxypropyl]sulfamates under the action of an alkaline agent followed by alcoholysis of the resulting sulfamic acids.
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
申请人:OOST Thorsten
公开号:US20140057916A1
公开(公告)日:2014-02-27
This invention relates to substituted 4-pyridones of formula 1
and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
Disclosed are compounds and pharmaceutically acceptable salts of Formula I
wherein A, Q
1
, Q
2
, Q
3
, R
31
, and R
41
are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS
申请人:Syngenta Crop Protection AG
公开号:US20200315174A1
公开(公告)日:2020-10-08
The invention relates to substituted thiophenyl uracils of general formula (I) or the salts (I) thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of cultivated plants and/or as plant growth regulators for influencing the growth of crops of cultivated plants.
Discovery of 1-[3-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-5-oxo-5<i>H</i>-benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-7-yl]-<i>N</i>-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met
作者:Alan B. Northrup、Matthew H. Katcher、Michael D. Altman、Melissa Chenard、Matthew H. Daniels、Sujal V. Deshmukh、Danielle Falcone、David J. Guerin、Harold Hatch、Chaomin Li、Wei Lu、Bart Lutterbach、Timothy J. Allison、Sangita B. Patel、John F. Reilly、Michael Reutershan、Keith W. Rickert、Craig Rosenstein、Stephen M. Soisson、Alexander A. Szewczak、Deborah Walker、Kevin Wilson、Jonathan R. Young、Bo-Sheng Pan、Christopher J. Dinsmore
DOI:10.1021/jm301619u
日期:2013.3.28
CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access 11r and analogues. We provide a rationale for the observed selectivity based on X-raycrystallographicevidence and discuss selectivity trends with additional examples. Importantly, 11r provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous
该报告记录了优先结合活化激酶构象的蛋白激酶特异性抑制剂的第一个实例:5 H-苯并[4,5]环庚[1,2 - b ]吡啶-5-酮11r(MK-8033) ,这是一种正在研究中的c-Met / Ron双重抑制剂,可用于治疗癌症。11r的设计基于减少该结构类别成员对CYP3A4(TDI)的时间依赖性抑制的愿望。开发了一种新颖的两步合成苄基磺酰胺的方法,以访问11r和类似物。我们根据X射线晶体学证据为观察到的选择性提供了理论依据,并与其他实例讨论了选择性趋势。重要的是11r 在c-Met扩增(GTL-16)皮下肿瘤异种移植模型中提供了对肿瘤生长的完全抑制作用,并且由于对c-Met的一系列致癌性激活突变具有同等效力,因此与无活性形式的激酶抑制剂相比可能具有优势-Met抑制剂不与活性激酶构象优先结合。
One-Pot Parallel Synthesis of 5-(Dialkylamino)tetrazoles
作者:Olena Savych、Yuliya O. Kuchkovska、Andrey V. Bogolyubsky、Anzhelika I. Konovets、Kateryna E. Gubina、Sergey E. Pipko、Anton V. Zhemera、Alexander V. Grishchenko、Dmytro N. Khomenko、Volodymyr S. Brovarets、Roman Doroschuk、Yurii S. Moroz、Oleksandr O. Grygorenko
DOI:10.1021/acscombsci.9b00120
日期:2019.9.9
Two protocols for the combinatorial synthesis of 5-(dialkylamino)tetrazoles were developed. The best success rate (67%) was shown by the method that used primary and secondary amines, 2,2,2-trifluoroethylthiocarbamate, and sodium azide as the starting reagents. The key steps included the formation of unsymmetrical thiourea, subsequent alkylation with 1,3-propane sultone and cyclization with azide anion